In the fight against pancreatic cancer, clinical trials often provide the best treatment options.
Our signature PurpleStride run/walk events raise spirits, awareness and funds in communities nationwide.
Give a patient, a caregiver, a researcher, the power of hope with one simple act.
Spark the scientific breakthroughs that innovate treatments to improve the lives of patients.
Fund a research grant today.
Call (877) 272-6226, email email@example.com or
Learn about the people and passion that drives PanCAN.
by Kristin Reynolds — May 16, 2022
PanCAN President and CEO Julie Fleshman, JD, MBA
PanCAN Precision Promise is our adaptive clinical trial created to bring better treatments to pancreatic cancer patients faster. The design of the trial makes it more efficient, requiring fewer patients and less time than a traditional clinical trial – helping us more quickly identify which treatments are most effective.
Since opening in October 2020 at 12 leading institutions nationwide, PanCAN Precision Promise has expanded to 20 sites and enrolled over 180 patients. By early 2023, 30 sites nationwide will offer the Precision Promise clinical trial to eligible patients.
Here, during Cancer Research Month, PanCAN President and CEO Julie Fleshman, JD, MBA, shares the latest updates on PanCAN Precision Promise.
Clinical trials are the only way to determine whether an experimental treatment option is safe and effective. All treatments available today were tested through clinical trials and then approved by the FDA. And evidence shows that pancreatic cancer patients who participate in clinical research have better outcomes. At PanCAN, we strongly recommend that patients discuss with their healthcare team if clinical trials are an option for them at diagnosis as well as during every treatment decision.
Progress for pancreatic cancer patients has not been fast enough. New treatment options are needed for patients to live longer, and those had not been happening at the pace we wanted to see.
Clinical trials are critical, but there are challenges with the traditional clinical trial process. It’s costly, it’s slow and the results don’t necessarily build on each other – the field hasn’t been learning from them like it should.
At PanCAN, we’ve never shied away from trying something different. So, we began thinking about a new approach to pancreatic cancer clinical trials.
We had several goals – to create a clinical trial design where each finding informed the next one, that learned from every patient and that put the patient at the center of every decision. A design that took less time and required fewer patients to test a treatment, and a design that would cost less money so it could de-risk pancreatic cancer drug development for pharmaceutical companies.
The adaptive design of Precision Promise is different than standard clinical trials. Meaning, with Precision Promise, if a drug is not working, it can be pulled from the trial and another treatment can take its place. And if a drug is working, it can move more quickly to the FDA for potential approval.
Also, multiple treatments can be tested at the same time, and only 175 patients are needed in order to know if a treatment is working.
Most importantly, our number-one goal with Precision Promise is to transform outcomes for pancreatic cancer patients.
Precision Promise opened in October 2020 and began enrolling eligible patients at 12 world-class cancer treatment institutions across the country. Since then, over 180 patients have been enrolled. Today patients can enroll at one of 20 sites in the United States.
By early 2023, we expect to operate Precision Promise at 30 sites nationwide.
In expanding, we focused on recruiting sites in the South and Midwest because they were geographic areas where we lacked a strong presence. We also focused on sites that have high proportions of minority populations and established minority outreach programs, and it was important to us to expand access of the trial to typically underserved communities.
Join us on Thursday, May 26, for a free webinar, “The Impact of Your Gifts: How You’re Advancing Pancreatic Cancer Research.” Julie Fleshman will moderate, and PanCAN Chief Science Officer Lynn Matrisian, PhD, MBA, will serve on the panel alongside noted researchers and physicians who will discuss PanCAN Precision Promise, PanCAN Early Detection Initiative and more. You will also hear from a PanCAN donor about why funding pancreatic cancer research is important to her.
One of the goals of Precision Promise is to win faster and fail faster. We want to get new treatments that work to patients faster, but we also want to stop testing treatments that don’t work. Throughout the design and execution of the trial, patients and their safety are at the center of every decision.
Recently, the expert Data Safety Monitoring Board (DSMB) of oncology specialists and statisticians that regularly watches patient outcomes and reports of side effects to determine whether a treatment should continue in Precision Promise, informed us that enrollment of patients in the first experimental treatment tested within the trial had been discontinued. Patients treated with it alone showed a lower overall survival rate than patients treated with standard chemotherapy.
This was disappointing news. But Precision Promise’s adaptive design did exactly what it is supposed to do. It determined more quickly than a traditional trial would have done that this treatment wasn’t working and discontinued giving it to patients. Precision Promise is functioning as it was intended: to learn faster with fewer patients.
Thanks to the biopharma company Abbvie, patients in Precision Promise who are identified as having pancreatic enzyme insufficiency have access to free pancreatic enzyme supplements while they’re in the study.
Pancreatic enzyme replacement therapy can be critical to patients’ quality of life, but enzymes can be very expensive, many insurance companies cover only a small portion of the cost, and unfortunately, there are still many patients who aren’t aware of the benefits of pancreatic enzymes.
Additionally, patients are benefiting from best practices in pain management – which is about comfort, quality of life and well-being. Last year, our Precision Promise Supportive Care Committee published a paper in The Oncologist that outlined the management of pancreatic cancer-associated pain.
Importantly, these are establishing best practices that will benefit patients treated outside of Precision Promise, too.
Our donors are the most committed, generous and passionate and share our vision of creating a world where all pancreatic cancer patients thrive. Precision Promise is one initiative that is going to get us there, our Early Detection Initiative is another, and our Research Grants Program is yet another. Not to mention all of our other scientific and clinical initiatives and resources for patients, from PanCAN Patient Services, to our Know Your Tumor® precision medicine service, Clinical Trial Finder and Patient Registry.
I am so grateful for your gifts to PanCAN because they truly are changing patients’ lives. Thank you!
7 Pancreatic Cancer Symptoms and Signs You Should Know
Alex Trebek Shares His Pancreatic Cancer Journey
7 Scientists Receive PanCAN Research Grants
8 Treatment Side Effects to Know
Friday Fix: Here’s the Truth About Cleanses
PanCAN Precision PromiseSM – Learnings, Expanding the Trial and More
PanCAN’s Early Detection Initiative: New Developments and What’s Next
Sea of Purple Coast to Coast
See You Tomorrow at PanCAN PurpleStride 2022!
Cancer Research Month: Progress Toward a World Where Pancreatic Cancer Patients Thrive
No one should face pancreatic cancer alone. Learn how we can support you.
Mon – Fri, 7 a.m. – 5 p.m. PST
You can also contact us using the below form.
Follow us on social media.
Get the latest news and updates from the Pancreatic Cancer Action Network.
1500 Rosecrans Avenue, Suite 200
Manhattan Beach, CA 90266 – Map
Phone: (310) 725-0025
Toll Free: (877) 573-9971
Fax: (310) 725-0029
Gear, apparel, accessories and more to show off your purple pride.
Get Our Latest News!
Pancreatic Cancer Action Network®, PanCAN®, PurpleStride®, Wage Hope®, Know Your Tumor®, Powerful Knowledge. Personal Treatment.®, Precision Promise℠ and Demand Better For Patients. For Survival.℠ are the trademarks of the Pancreatic Cancer Action Network, Inc.
The Pancreatic Cancer Action Network is registered as a 501©3 nonprofit organization. Contributions to the Pancreatic Cancer Action Network are tax-deductible to the extent permitted by law. The Pancreatic Cancer Action Network’s tax identification number is #33-0841281.